GENETIC ANALYSIS NK -60 (8V8) — Net Asset Quality Index
GENETIC ANALYSIS NK -60 (8V8) has a Net Asset Quality Index of 46.4% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €44.64 Million minus total liabilities of €23.93 Million yields net assets of €20.71 Million. A higher index indicates a stronger, lower-leverage balance sheet. Read total liabilities of GENETIC ANALYSIS NK -60 for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
GENETIC ANALYSIS NK -60 Net Asset Quality Index Over Time (2021–2025)
This chart shows how GENETIC ANALYSIS NK -60's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of June 2026, the index stands at 46.4%, representing net assets of €20.71 Million against total assets of €44.64 Million EUR. For live market cap and overall valuation, see 8V8 market cap.
Annual Net Asset Quality Index for GENETIC ANALYSIS NK -60 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for GENETIC ANALYSIS NK -60 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. See what is GENETIC ANALYSIS NK -60's book value for net asset value and shareholders' equity analysis.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 51.6% | €27.08 Million | €52.45 Million | €25.37 Million | ▼ -1.4 pp |
| 2024 | 53.1% | €22.49 Million | €42.38 Million | €19.88 Million | ▼ -6.7 pp |
| 2023 | 59.8% | €32.00 Million | €53.49 Million | €21.49 Million | ▼ -8.7 pp |
| 2022 | 68.5% | €44.14 Million | €64.42 Million | €20.28 Million | ▼ -17.8 pp |
| 2021 | 86.3% | €72.09 Million | €83.49 Million | €11.40 Million | — |